Ann Thor
Concepts (434)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 64 | 2022 | 1781 | 4.440 |
Why?
| Receptor, ErbB-2 | 24 | 2018 | 301 | 3.010 |
Why?
| Metformin | 10 | 2018 | 283 | 2.460 |
Why?
| Tamoxifen | 10 | 2020 | 187 | 1.720 |
Why?
| Receptors, Estrogen | 15 | 2020 | 368 | 1.610 |
Why?
| Receptor, ErbB-3 | 8 | 2016 | 42 | 1.500 |
Why?
| Cell Proliferation | 15 | 2018 | 2158 | 1.320 |
Why?
| Genes, erbB-2 | 8 | 2013 | 24 | 1.270 |
Why?
| Mammary Neoplasms, Experimental | 6 | 2017 | 61 | 1.210 |
Why?
| Apoptosis | 20 | 2018 | 2319 | 0.900 |
Why?
| Cell Line, Tumor | 22 | 2020 | 2669 | 0.840 |
Why?
| Thyroid Hormones | 1 | 2020 | 54 | 0.780 |
Why?
| Hormone Replacement Therapy | 1 | 2020 | 75 | 0.760 |
Why?
| Up-Regulation | 3 | 2020 | 793 | 0.760 |
Why?
| Triple Negative Breast Neoplasms | 3 | 2016 | 151 | 0.710 |
Why?
| Mammary Neoplasms, Animal | 3 | 2018 | 29 | 0.700 |
Why?
| Disease-Free Survival | 11 | 2020 | 633 | 0.670 |
Why?
| Tumor Suppressor Protein p53 | 13 | 2011 | 444 | 0.640 |
Why?
| Immunohistochemistry | 24 | 2017 | 1603 | 0.640 |
Why?
| Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 47 | 0.620 |
Why?
| Hypoglycemic Agents | 3 | 2017 | 621 | 0.610 |
Why?
| Biomarkers, Tumor | 10 | 2021 | 984 | 0.600 |
Why?
| Testicular Neoplasms | 3 | 2023 | 82 | 0.600 |
Why?
| Gene Expression Regulation, Neoplastic | 18 | 2021 | 1114 | 0.600 |
Why?
| ErbB Receptors | 4 | 2010 | 565 | 0.590 |
Why?
| Claudins | 1 | 2016 | 21 | 0.570 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2015 | 1365 | 0.560 |
Why?
| Antineoplastic Agents | 9 | 2018 | 1929 | 0.550 |
Why?
| Receptor, IGF Type 1 | 3 | 2016 | 55 | 0.550 |
Why?
| Transcriptome | 1 | 2020 | 704 | 0.540 |
Why?
| Carcinogenesis | 1 | 2016 | 157 | 0.510 |
Why?
| Prognosis | 17 | 2016 | 3245 | 0.500 |
Why?
| Carcinoma, Ductal, Breast | 5 | 2002 | 70 | 0.500 |
Why?
| Cell Cycle | 4 | 2013 | 509 | 0.490 |
Why?
| Estradiol | 2 | 2009 | 462 | 0.480 |
Why?
| Trastuzumab | 7 | 2016 | 90 | 0.480 |
Why?
| Lymphatic Metastasis | 16 | 2021 | 227 | 0.470 |
Why?
| Caspases | 4 | 2009 | 259 | 0.470 |
Why?
| Genistein | 2 | 2010 | 20 | 0.460 |
Why?
| Female | 64 | 2022 | 58205 | 0.430 |
Why?
| Antineoplastic Agents, Hormonal | 5 | 2020 | 138 | 0.430 |
Why?
| Signal Transduction | 15 | 2018 | 4136 | 0.430 |
Why?
| Receptors, Steroid | 1 | 2012 | 55 | 0.430 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2012 | 76 | 0.420 |
Why?
| Drug Resistance, Neoplasm | 9 | 2016 | 671 | 0.400 |
Why?
| Neoplasm Invasiveness | 7 | 2016 | 399 | 0.390 |
Why?
| STAT3 Transcription Factor | 1 | 2012 | 175 | 0.380 |
Why?
| Genes, p53 | 5 | 2000 | 53 | 0.380 |
Why?
| Humans | 81 | 2023 | 109574 | 0.370 |
Why?
| Neoplasm Proteins | 5 | 2016 | 382 | 0.350 |
Why?
| Glucose | 1 | 2013 | 872 | 0.340 |
Why?
| Glycoproteins | 2 | 2005 | 296 | 0.330 |
Why?
| Intracellular Signaling Peptides and Proteins | 2 | 2010 | 384 | 0.330 |
Why?
| Mice, Transgenic | 8 | 2018 | 1591 | 0.320 |
Why?
| Mammary Tumor Virus, Mouse | 2 | 2004 | 18 | 0.320 |
Why?
| MCF-7 Cells | 4 | 2020 | 113 | 0.300 |
Why?
| MicroRNAs | 4 | 2021 | 580 | 0.300 |
Why?
| Carcinoma | 4 | 1995 | 193 | 0.300 |
Why?
| Doxorubicin | 9 | 2011 | 285 | 0.280 |
Why?
| Polymerase Chain Reaction | 6 | 2021 | 853 | 0.280 |
Why?
| Bromodeoxyuridine | 2 | 1999 | 71 | 0.280 |
Why?
| Mice | 16 | 2022 | 12565 | 0.270 |
Why?
| Protein Kinase Inhibitors | 3 | 2016 | 841 | 0.270 |
Why?
| Antibodies, Monoclonal | 6 | 2013 | 1052 | 0.270 |
Why?
| Animals | 22 | 2022 | 29555 | 0.270 |
Why?
| Xenograft Model Antitumor Assays | 3 | 2020 | 728 | 0.260 |
Why?
| Tyrosine | 2 | 2007 | 185 | 0.260 |
Why?
| Radiation Tolerance | 1 | 2005 | 97 | 0.260 |
Why?
| Quinazolines | 2 | 2016 | 241 | 0.250 |
Why?
| Phosphorylation | 5 | 2011 | 1468 | 0.250 |
Why?
| Cocarcinogenesis | 1 | 2003 | 8 | 0.240 |
Why?
| Isoflavones | 1 | 2003 | 22 | 0.240 |
Why?
| Cell Survival | 5 | 2018 | 959 | 0.240 |
Why?
| Paclitaxel | 4 | 2015 | 186 | 0.240 |
Why?
| Seminoma | 1 | 2023 | 15 | 0.240 |
Why?
| Chromosomes | 1 | 2003 | 73 | 0.230 |
Why?
| Multivariate Analysis | 7 | 2005 | 1455 | 0.230 |
Why?
| Receptors, Progesterone | 5 | 2012 | 315 | 0.230 |
Why?
| Cyclins | 2 | 2000 | 69 | 0.220 |
Why?
| Chromosomes, Human, Pair 8 | 1 | 2002 | 34 | 0.220 |
Why?
| Chromosome Aberrations | 1 | 2002 | 126 | 0.220 |
Why?
| Enzyme Activation | 3 | 2009 | 711 | 0.210 |
Why?
| Ki-67 Antigen | 3 | 2014 | 102 | 0.210 |
Why?
| Cyclophosphamide | 7 | 2011 | 217 | 0.210 |
Why?
| Breast | 4 | 2018 | 126 | 0.210 |
Why?
| Orchiectomy | 1 | 2021 | 56 | 0.210 |
Why?
| Diet | 3 | 2018 | 1053 | 0.210 |
Why?
| Retroperitoneal Neoplasms | 1 | 2021 | 16 | 0.210 |
Why?
| Neoplasm Staging | 8 | 2021 | 1105 | 0.200 |
Why?
| Obesity | 4 | 2022 | 2619 | 0.200 |
Why?
| Survival Analysis | 7 | 2005 | 1213 | 0.200 |
Why?
| Rats | 7 | 2022 | 5346 | 0.200 |
Why?
| Neoplastic Stem Cells | 2 | 2014 | 325 | 0.190 |
Why?
| Teratoma | 1 | 2021 | 85 | 0.190 |
Why?
| Phosphatidylinositol 3-Kinases | 3 | 2011 | 304 | 0.190 |
Why?
| TOR Serine-Threonine Kinases | 3 | 2012 | 354 | 0.190 |
Why?
| Mice, SCID | 1 | 2020 | 276 | 0.190 |
Why?
| Ovarian Neoplasms | 4 | 1995 | 381 | 0.190 |
Why?
| Middle Aged | 26 | 2021 | 26782 | 0.190 |
Why?
| Mice, Inbred NOD | 1 | 2020 | 335 | 0.180 |
Why?
| Carcinoma, Papillary | 1 | 1999 | 61 | 0.180 |
Why?
| Antigens, Neoplasm | 2 | 2009 | 156 | 0.180 |
Why?
| Autism Spectrum Disorder | 1 | 2023 | 258 | 0.180 |
Why?
| Mitotic Index | 1 | 1999 | 24 | 0.180 |
Why?
| Proto-Oncogene Proteins | 5 | 2008 | 593 | 0.180 |
Why?
| Chemotherapy, Adjuvant | 5 | 2015 | 288 | 0.180 |
Why?
| Receptors, Androgen | 2 | 2017 | 124 | 0.170 |
Why?
| Aromatase | 1 | 2018 | 29 | 0.170 |
Why?
| Drug Synergism | 3 | 2018 | 317 | 0.170 |
Why?
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 52 | 0.170 |
Why?
| Kaplan-Meier Estimate | 1 | 2020 | 847 | 0.160 |
Why?
| HSP90 Heat-Shock Proteins | 1 | 2018 | 44 | 0.160 |
Why?
| Phenylthiohydantoin | 2 | 2017 | 40 | 0.160 |
Why?
| Ovariectomy | 4 | 2022 | 119 | 0.160 |
Why?
| Fluorouracil | 5 | 2009 | 133 | 0.160 |
Why?
| Down-Regulation | 3 | 2010 | 569 | 0.160 |
Why?
| Tumor Burden | 4 | 2022 | 244 | 0.160 |
Why?
| In Situ Hybridization, Fluorescence | 4 | 2008 | 308 | 0.160 |
Why?
| Poly(ADP-ribose) Polymerases | 2 | 2009 | 83 | 0.160 |
Why?
| Cell Division | 4 | 2005 | 679 | 0.160 |
Why?
| Estrogen Receptor alpha | 2 | 2018 | 117 | 0.150 |
Why?
| Organic Cation Transport Proteins | 1 | 2017 | 28 | 0.150 |
Why?
| Postmenopause | 5 | 2022 | 301 | 0.150 |
Why?
| Triazoles | 1 | 2018 | 128 | 0.150 |
Why?
| Caspase 3 | 3 | 2006 | 238 | 0.150 |
Why?
| Smad Proteins | 1 | 2016 | 30 | 0.140 |
Why?
| Gene Knock-In Techniques | 1 | 2016 | 36 | 0.140 |
Why?
| Ovary | 1 | 2017 | 202 | 0.140 |
Why?
| Calcitriol | 1 | 2016 | 51 | 0.140 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 246 | 0.140 |
Why?
| Estrogens | 1 | 2018 | 305 | 0.140 |
Why?
| Proteins | 2 | 1992 | 836 | 0.140 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2016 | 102 | 0.140 |
Why?
| Drug Screening Assays, Antitumor | 2 | 2016 | 180 | 0.130 |
Why?
| Gene Amplification | 2 | 2009 | 97 | 0.130 |
Why?
| Mental Disorders | 1 | 2023 | 893 | 0.130 |
Why?
| Fatty Acid Synthase, Type I | 1 | 2014 | 7 | 0.130 |
Why?
| Mice, Knockout | 1 | 2020 | 2224 | 0.130 |
Why?
| Disease Progression | 6 | 2018 | 2212 | 0.130 |
Why?
| Immunoradiometric Assay | 1 | 1994 | 1 | 0.130 |
Why?
| Cathepsin D | 1 | 1994 | 7 | 0.130 |
Why?
| Antibodies, Monoclonal, Humanized | 4 | 2013 | 623 | 0.130 |
Why?
| Postpartum Period | 2 | 2014 | 261 | 0.130 |
Why?
| Adenocarcinoma | 3 | 2012 | 661 | 0.130 |
Why?
| Immunoprecipitation | 2 | 2011 | 149 | 0.130 |
Why?
| Androgen Receptor Antagonists | 1 | 2014 | 31 | 0.120 |
Why?
| Tumor Cells, Cultured | 5 | 2009 | 825 | 0.120 |
Why?
| Insulin-Like Growth Factor I | 1 | 2016 | 276 | 0.120 |
Why?
| Transforming Growth Factor beta | 1 | 2016 | 399 | 0.120 |
Why?
| Androgen Antagonists | 1 | 2014 | 76 | 0.120 |
Why?
| Receptor, ErbB-4 | 2 | 2010 | 19 | 0.120 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2010 | 59 | 0.120 |
Why?
| Disease Models, Animal | 4 | 2017 | 3439 | 0.110 |
Why?
| Blotting, Western | 3 | 2011 | 1135 | 0.110 |
Why?
| Nucleic Acid Hybridization | 2 | 2003 | 148 | 0.110 |
Why?
| Vitamin D | 1 | 2016 | 348 | 0.110 |
Why?
| Overnutrition | 1 | 2012 | 37 | 0.110 |
Why?
| RNA, Messenger | 4 | 2016 | 2420 | 0.110 |
Why?
| Aminosalicylic Acids | 1 | 2012 | 7 | 0.110 |
Why?
| DNA, Neoplasm | 6 | 2005 | 146 | 0.110 |
Why?
| Benzenesulfonates | 1 | 2012 | 20 | 0.110 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2007 | 193 | 0.110 |
Why?
| Gene Expression Profiling | 2 | 2016 | 1460 | 0.110 |
Why?
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1992 | 43 | 0.110 |
Why?
| Chromones | 1 | 2011 | 35 | 0.110 |
Why?
| Dasatinib | 1 | 2011 | 44 | 0.110 |
Why?
| Genital Diseases, Female | 1 | 1991 | 27 | 0.100 |
Why?
| Mitosis | 3 | 2001 | 133 | 0.100 |
Why?
| Fluoxymesterone | 1 | 1991 | 3 | 0.100 |
Why?
| Cohort Studies | 2 | 2020 | 4802 | 0.100 |
Why?
| Proportional Hazards Models | 4 | 2005 | 1097 | 0.100 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2012 | 158 | 0.100 |
Why?
| S Phase | 2 | 2010 | 61 | 0.100 |
Why?
| Thiazoles | 1 | 2011 | 109 | 0.100 |
Why?
| Morpholines | 1 | 2011 | 99 | 0.100 |
Why?
| Reagent Kits, Diagnostic | 1 | 1991 | 42 | 0.100 |
Why?
| Genital Neoplasms, Female | 1 | 1991 | 62 | 0.100 |
Why?
| Flow Cytometry | 3 | 2007 | 850 | 0.100 |
Why?
| Weight Gain | 3 | 2022 | 488 | 0.100 |
Why?
| Neoplasm Metastasis | 5 | 2005 | 562 | 0.100 |
Why?
| Chromosomes, Human, Pair 17 | 3 | 2002 | 58 | 0.100 |
Why?
| Proto-Oncogenes | 1 | 1989 | 27 | 0.090 |
Why?
| Antibiotics, Antineoplastic | 2 | 2009 | 106 | 0.090 |
Why?
| Radioisotopes | 1 | 1989 | 28 | 0.090 |
Why?
| Aged | 12 | 2015 | 19244 | 0.090 |
Why?
| Adult | 15 | 2021 | 29923 | 0.090 |
Why?
| Dose-Response Relationship, Drug | 2 | 2008 | 1930 | 0.090 |
Why?
| Anthracyclines | 1 | 2009 | 38 | 0.090 |
Why?
| DNA Topoisomerases, Type II | 1 | 2009 | 43 | 0.090 |
Why?
| DNA-Binding Proteins | 2 | 2009 | 1168 | 0.090 |
Why?
| Treatment Outcome | 5 | 2007 | 8988 | 0.090 |
Why?
| Gene Deletion | 2 | 2002 | 291 | 0.080 |
Why?
| Mutation | 3 | 1995 | 2977 | 0.080 |
Why?
| Pyrimidines | 1 | 2011 | 372 | 0.080 |
Why?
| Epithelial Cells | 1 | 2014 | 882 | 0.080 |
Why?
| MAP Kinase Signaling System | 1 | 2010 | 273 | 0.080 |
Why?
| AMP-Activated Protein Kinases | 1 | 2009 | 168 | 0.080 |
Why?
| RNA, Small Interfering | 2 | 2007 | 531 | 0.080 |
Why?
| Protein Structure, Tertiary | 1 | 2009 | 653 | 0.080 |
Why?
| Transcription Factors | 2 | 2008 | 1319 | 0.080 |
Why?
| Mice, Nude | 1 | 2009 | 614 | 0.080 |
Why?
| Gene Dosage | 1 | 2008 | 136 | 0.080 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 921 | 0.080 |
Why?
| Immunoenzyme Techniques | 3 | 1999 | 189 | 0.080 |
Why?
| Time Factors | 4 | 2015 | 6376 | 0.080 |
Why?
| Energy Metabolism | 1 | 2012 | 853 | 0.070 |
Why?
| Proto-Oncogene Proteins c-akt | 3 | 2016 | 408 | 0.070 |
Why?
| Enzyme Precursors | 1 | 2006 | 13 | 0.070 |
Why?
| Mitochondria | 3 | 2008 | 724 | 0.070 |
Why?
| Epigenesis, Genetic | 1 | 2010 | 483 | 0.070 |
Why?
| Receptor, Notch1 | 1 | 2006 | 63 | 0.070 |
Why?
| Herpesvirus 1, Human | 1 | 2006 | 58 | 0.070 |
Why?
| Multigene Family | 2 | 2003 | 167 | 0.070 |
Why?
| Lamin Type B | 1 | 2005 | 6 | 0.070 |
Why?
| Herpes Simplex | 1 | 2006 | 81 | 0.070 |
Why?
| Tumor Microenvironment | 2 | 2018 | 386 | 0.070 |
Why?
| Age Factors | 3 | 2003 | 2922 | 0.070 |
Why?
| Cell Nucleolus | 1 | 2005 | 17 | 0.070 |
Why?
| Nitriles | 2 | 2017 | 158 | 0.070 |
Why?
| Benzamides | 2 | 2017 | 171 | 0.070 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2007 | 106 | 0.070 |
Why?
| Protein Kinases | 1 | 2006 | 227 | 0.070 |
Why?
| Follow-Up Studies | 4 | 2007 | 4461 | 0.070 |
Why?
| Feedback | 1 | 2005 | 138 | 0.070 |
Why?
| Aged, 80 and over | 4 | 2000 | 6464 | 0.060 |
Why?
| RNA Interference | 3 | 2015 | 432 | 0.060 |
Why?
| Tacrolimus Binding Protein 1A | 1 | 2003 | 5 | 0.060 |
Why?
| Tacrolimus Binding Proteins | 1 | 2003 | 14 | 0.060 |
Why?
| Predictive Value of Tests | 4 | 2011 | 1767 | 0.060 |
Why?
| Rats, Wistar | 2 | 2017 | 358 | 0.060 |
Why?
| Mice, Inbred Strains | 1 | 2004 | 294 | 0.060 |
Why?
| Estrogens, Non-Steroidal | 1 | 2003 | 4 | 0.060 |
Why?
| Genes, Tumor Suppressor | 1 | 2003 | 69 | 0.060 |
Why?
| Adipose Tissue | 2 | 2018 | 612 | 0.060 |
Why?
| Lymph Node Excision | 2 | 2021 | 111 | 0.060 |
Why?
| Phytoestrogens | 1 | 2003 | 15 | 0.060 |
Why?
| Plant Preparations | 1 | 2003 | 20 | 0.060 |
Why?
| Cell Line | 2 | 2003 | 2310 | 0.060 |
Why?
| Estrogen Antagonists | 1 | 2003 | 37 | 0.060 |
Why?
| Actins | 1 | 2005 | 344 | 0.060 |
Why?
| Chromosome Banding | 1 | 2002 | 18 | 0.060 |
Why?
| Anticarcinogenic Agents | 1 | 2003 | 73 | 0.060 |
Why?
| Chromosomes, Human, Pair 16 | 1 | 2002 | 28 | 0.060 |
Why?
| Mammary Glands, Animal | 1 | 2003 | 133 | 0.060 |
Why?
| Rodentia | 1 | 2022 | 46 | 0.060 |
Why?
| Transfection | 3 | 2015 | 780 | 0.060 |
Why?
| 3' Untranslated Regions | 2 | 2014 | 138 | 0.060 |
Why?
| Trefoil Factor-1 | 2 | 1992 | 2 | 0.050 |
Why?
| Nuclear Proteins | 2 | 2000 | 536 | 0.050 |
Why?
| alpha-Fetoproteins | 1 | 2021 | 33 | 0.050 |
Why?
| Fallopian Tubes | 2 | 1991 | 23 | 0.050 |
Why?
| In Situ Nick-End Labeling | 1 | 2001 | 124 | 0.050 |
Why?
| Sweden | 1 | 2021 | 44 | 0.050 |
Why?
| Chorionic Gonadotropin | 1 | 2021 | 79 | 0.050 |
Why?
| RNA, Catalytic | 1 | 2002 | 157 | 0.050 |
Why?
| Plasmids | 1 | 2002 | 306 | 0.050 |
Why?
| Neoplasm, Residual | 1 | 2021 | 82 | 0.050 |
Why?
| RNA Stability | 1 | 2021 | 75 | 0.050 |
Why?
| Antigens, Nuclear | 1 | 2000 | 16 | 0.050 |
Why?
| Breast Diseases | 1 | 2000 | 16 | 0.050 |
Why?
| Enhancer Elements, Genetic | 1 | 2000 | 124 | 0.050 |
Why?
| Reproducibility of Results | 2 | 2021 | 2713 | 0.050 |
Why?
| Telomerase | 1 | 2001 | 177 | 0.050 |
Why?
| Integrin beta3 | 2 | 2013 | 10 | 0.050 |
Why?
| Tumor Suppressor Proteins | 2 | 1992 | 261 | 0.050 |
Why?
| Trans-Activators | 1 | 2000 | 270 | 0.040 |
Why?
| N-Glycosyl Hydrolases | 1 | 1998 | 6 | 0.040 |
Why?
| DNA Glycosylases | 1 | 1998 | 6 | 0.040 |
Why?
| Methylnitrosourea | 1 | 2018 | 6 | 0.040 |
Why?
| Retrospective Studies | 4 | 2005 | 11697 | 0.040 |
Why?
| Loss of Function Mutation | 1 | 2018 | 34 | 0.040 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2018 | 41 | 0.040 |
Why?
| Case-Control Studies | 2 | 2023 | 2989 | 0.040 |
Why?
| Antibodies | 1 | 2000 | 333 | 0.040 |
Why?
| NF-kappa B | 1 | 2002 | 630 | 0.040 |
Why?
| Codon | 3 | 1993 | 80 | 0.040 |
Why?
| Half-Life | 1 | 2018 | 138 | 0.040 |
Why?
| Stromal Cells | 1 | 2018 | 91 | 0.040 |
Why?
| Hyaluronan Receptors | 1 | 1998 | 76 | 0.040 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 136 | 0.040 |
Why?
| Organic Cation Transporter 2 | 1 | 2017 | 9 | 0.040 |
Why?
| Gene Expression | 3 | 2013 | 1365 | 0.040 |
Why?
| Antigens, CD | 2 | 2014 | 377 | 0.040 |
Why?
| Extracellular Matrix Proteins | 1 | 1998 | 115 | 0.040 |
Why?
| DNA Repair | 1 | 1998 | 178 | 0.040 |
Why?
| Steroids | 1 | 2017 | 148 | 0.040 |
Why?
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2016 | 11 | 0.040 |
Why?
| RNA | 1 | 2001 | 648 | 0.040 |
Why?
| Chromatography, Liquid | 1 | 2017 | 317 | 0.040 |
Why?
| Phosphatidylinositol 3-Kinase | 1 | 2015 | 21 | 0.030 |
Why?
| Oncogenes | 1 | 2016 | 116 | 0.030 |
Why?
| Survival Rate | 3 | 1998 | 1657 | 0.030 |
Why?
| Oncogene Proteins | 1 | 1995 | 48 | 0.030 |
Why?
| Cell Nucleus | 3 | 2006 | 510 | 0.030 |
Why?
| Homeodomain Proteins | 1 | 2018 | 415 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2017 | 568 | 0.030 |
Why?
| Testosterone | 1 | 2017 | 320 | 0.030 |
Why?
| Tosyl Compounds | 1 | 2014 | 17 | 0.030 |
Why?
| Integrin alpha6 | 1 | 2013 | 7 | 0.030 |
Why?
| Antigens, Differentiation, Myelomonocytic | 1 | 2014 | 43 | 0.030 |
Why?
| Leukocyte Common Antigens | 1 | 2014 | 66 | 0.030 |
Why?
| Mammary Glands, Human | 1 | 2014 | 65 | 0.030 |
Why?
| Analysis of Variance | 2 | 2014 | 1335 | 0.030 |
Why?
| Neoplasms | 2 | 2012 | 2055 | 0.030 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 269 | 0.030 |
Why?
| Parity | 1 | 2014 | 99 | 0.030 |
Why?
| Brain Neoplasms | 2 | 1993 | 982 | 0.030 |
Why?
| Immunoassay | 1 | 1994 | 91 | 0.030 |
Why?
| Sirolimus | 2 | 2006 | 190 | 0.030 |
Why?
| Premenopause | 1 | 2014 | 117 | 0.030 |
Why?
| Anilides | 1 | 2014 | 72 | 0.030 |
Why?
| Transplantation, Heterologous | 1 | 2014 | 185 | 0.030 |
Why?
| Interleukin-6 | 1 | 2017 | 637 | 0.030 |
Why?
| bcl-2-Associated X Protein | 2 | 2007 | 35 | 0.030 |
Why?
| Neovascularization, Pathologic | 1 | 1995 | 271 | 0.030 |
Why?
| Neoplasm Transplantation | 1 | 2014 | 217 | 0.030 |
Why?
| Organ Specificity | 1 | 2013 | 239 | 0.030 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 43 | 0.030 |
Why?
| Immune System | 1 | 2014 | 151 | 0.030 |
Why?
| Young Adult | 2 | 2021 | 10138 | 0.030 |
Why?
| Lactation | 1 | 2014 | 176 | 0.030 |
Why?
| Lipogenesis | 1 | 2012 | 70 | 0.030 |
Why?
| Point Mutation | 1 | 1993 | 200 | 0.030 |
Why?
| Astrocytoma | 1 | 1993 | 107 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2015 | 359 | 0.030 |
Why?
| Broad Ligament | 1 | 1991 | 2 | 0.030 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2007 | 1070 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2013 | 295 | 0.030 |
Why?
| Peritoneum | 1 | 1991 | 30 | 0.030 |
Why?
| Glycolysis | 1 | 2012 | 228 | 0.030 |
Why?
| Mucins | 1 | 1991 | 60 | 0.030 |
Why?
| Pilot Projects | 1 | 2015 | 1320 | 0.030 |
Why?
| Pregnancy Complications, Neoplastic | 1 | 1991 | 49 | 0.030 |
Why?
| Pregnancy | 2 | 2014 | 5275 | 0.030 |
Why?
| Blotting, Northern | 1 | 2010 | 172 | 0.030 |
Why?
| Evaluation Studies as Topic | 1 | 1991 | 193 | 0.020 |
Why?
| Hormones | 1 | 1991 | 129 | 0.020 |
Why?
| Soft Tissue Neoplasms | 1 | 1991 | 80 | 0.020 |
Why?
| Cells, Cultured | 2 | 2013 | 3582 | 0.020 |
Why?
| Glioblastoma | 1 | 1993 | 256 | 0.020 |
Why?
| In Situ Hybridization | 1 | 2010 | 304 | 0.020 |
Why?
| Precipitin Tests | 1 | 1989 | 73 | 0.020 |
Why?
| Prospective Studies | 1 | 2021 | 5949 | 0.020 |
Why?
| Risk Factors | 1 | 2003 | 8453 | 0.020 |
Why?
| Radionuclide Imaging | 1 | 1989 | 125 | 0.020 |
Why?
| Odds Ratio | 1 | 1992 | 954 | 0.020 |
Why?
| Protein Multimerization | 1 | 2010 | 141 | 0.020 |
Why?
| Lymph Nodes | 1 | 1991 | 309 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 683 | 0.020 |
Why?
| Drug Interactions | 1 | 2009 | 354 | 0.020 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2007 | 49 | 0.020 |
Why?
| Apoptotic Protease-Activating Factor 1 | 1 | 2007 | 2 | 0.020 |
Why?
| Cytochromes c | 1 | 2007 | 64 | 0.020 |
Why?
| Amino Acid Sequence | 3 | 1998 | 1579 | 0.020 |
Why?
| Biomarkers | 1 | 2017 | 3342 | 0.020 |
Why?
| Male | 3 | 2023 | 55563 | 0.020 |
Why?
| Caspase 10 | 1 | 2006 | 5 | 0.020 |
Why?
| Aging | 2 | 2002 | 1553 | 0.020 |
Why?
| Caspase 2 | 1 | 2006 | 14 | 0.020 |
Why?
| Caspase 8 | 1 | 2006 | 47 | 0.020 |
Why?
| Caspase 9 | 1 | 2006 | 47 | 0.020 |
Why?
| Cysteine Endopeptidases | 1 | 2006 | 51 | 0.020 |
Why?
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 11 | 0.020 |
Why?
| Caspase 7 | 1 | 2006 | 22 | 0.020 |
Why?
| Eukaryotic Initiation Factor-4E | 1 | 2006 | 25 | 0.020 |
Why?
| Vero Cells | 1 | 2006 | 51 | 0.020 |
Why?
| Cytosol | 1 | 2006 | 193 | 0.020 |
Why?
| Isoenzymes | 1 | 2007 | 284 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2010 | 991 | 0.020 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 182 | 0.020 |
Why?
| Base Sequence | 2 | 2003 | 1672 | 0.020 |
Why?
| Virus Assembly | 1 | 2006 | 77 | 0.020 |
Why?
| Adolescent | 2 | 2021 | 17117 | 0.020 |
Why?
| Protein Binding | 1 | 2010 | 1568 | 0.020 |
Why?
| Taxoids | 1 | 2004 | 94 | 0.020 |
Why?
| Mice, Inbred C57BL | 2 | 2003 | 4136 | 0.020 |
Why?
| Protein Processing, Post-Translational | 1 | 2006 | 350 | 0.020 |
Why?
| DNA, Complementary | 1 | 2003 | 233 | 0.010 |
Why?
| Melanoma, Experimental | 1 | 2003 | 86 | 0.010 |
Why?
| Cell Adhesion | 1 | 2003 | 385 | 0.010 |
Why?
| Platelet Membrane Glycoproteins | 1 | 2002 | 38 | 0.010 |
Why?
| Exons | 2 | 1993 | 278 | 0.010 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2002 | 54 | 0.010 |
Why?
| Gene Targeting | 1 | 2002 | 57 | 0.010 |
Why?
| Templates, Genetic | 1 | 2001 | 26 | 0.010 |
Why?
| Molecular Sequence Data | 2 | 1998 | 2292 | 0.010 |
Why?
| Substrate Specificity | 1 | 2002 | 284 | 0.010 |
Why?
| Mice, Inbred BALB C | 1 | 2003 | 847 | 0.010 |
Why?
| DNA Footprinting | 1 | 2000 | 19 | 0.010 |
Why?
| DNA, Superhelical | 1 | 2000 | 9 | 0.010 |
Why?
| Genes, erbB | 1 | 2000 | 2 | 0.010 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 2000 | 91 | 0.010 |
Why?
| Ploidies | 1 | 2000 | 19 | 0.010 |
Why?
| Proto-Oncogene Proteins c-ets | 1 | 2000 | 49 | 0.010 |
Why?
| Macromolecular Substances | 1 | 2000 | 139 | 0.010 |
Why?
| Pathology, Clinical | 1 | 2000 | 33 | 0.010 |
Why?
| Gene Silencing | 1 | 2000 | 159 | 0.010 |
Why?
| Multicenter Studies as Topic | 1 | 2000 | 223 | 0.010 |
Why?
| Genetic Therapy | 1 | 2000 | 234 | 0.010 |
Why?
| Receptors, Cell Surface | 1 | 2000 | 283 | 0.010 |
Why?
| Forecasting | 1 | 2000 | 370 | 0.010 |
Why?
| Binding Sites | 1 | 2000 | 960 | 0.010 |
Why?
| Nucleic Acid Conformation | 1 | 2000 | 501 | 0.010 |
Why?
| ras Proteins | 1 | 1998 | 126 | 0.010 |
Why?
| Chromosomes, Human, Pair 13 | 1 | 1996 | 17 | 0.010 |
Why?
| Chromosomes, Human, Pair 3 | 1 | 1996 | 50 | 0.010 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 1996 | 61 | 0.010 |
Why?
| Adenine | 1 | 1998 | 198 | 0.010 |
Why?
| Immunoblotting | 1 | 1997 | 281 | 0.010 |
Why?
| Heterozygote | 1 | 1996 | 240 | 0.010 |
Why?
| Hyaluronic Acid | 1 | 1998 | 186 | 0.010 |
Why?
| Melanoma | 1 | 2002 | 577 | 0.010 |
Why?
| Societies, Medical | 1 | 2000 | 688 | 0.010 |
Why?
| United States | 2 | 2004 | 12165 | 0.010 |
Why?
| Protein Isoforms | 1 | 1997 | 315 | 0.010 |
Why?
| Transcription, Genetic | 1 | 2000 | 1022 | 0.010 |
Why?
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 29 | 0.010 |
Why?
| Factor VIII | 1 | 1995 | 51 | 0.010 |
Why?
| Cyclin D1 | 1 | 1995 | 58 | 0.010 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2000 | 1163 | 0.010 |
Why?
| Single-Blind Method | 1 | 1995 | 259 | 0.010 |
Why?
| Observer Variation | 1 | 1995 | 294 | 0.010 |
Why?
| Alleles | 1 | 1996 | 694 | 0.010 |
Why?
| Biopsy | 1 | 1995 | 1027 | 0.010 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 1991 | 53 | 0.010 |
Why?
| Peripheral Nerves | 1 | 1991 | 63 | 0.010 |
Why?
| DNA | 1 | 1996 | 1104 | 0.010 |
Why?
| Risk Assessment | 1 | 2000 | 2976 | 0.010 |
Why?
| Protein Conformation | 1 | 1993 | 636 | 0.010 |
Why?
| Polymorphism, Genetic | 1 | 1993 | 576 | 0.010 |
Why?
| Lung Neoplasms | 1 | 2002 | 2166 | 0.010 |
Why?
| Glioma | 1 | 1991 | 289 | 0.000 |
Why?
| Cerebral Cortex | 1 | 1991 | 486 | 0.000 |
Why?
| Child | 1 | 1993 | 16611 | 0.000 |
Why?
|
|
Thor's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|